Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kyto Technology & Life Science, Inc.KBPH · Entity 16492 | 10% owner | March 31, 2010 | September 23, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kyto Technology & Life Science, Inc.
Report date March 31, 2010 · Filed September 23, 2014
Jointly reported with BRISTOL MYERS SQUIBB CO
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Medarex, L.L.C. | 1,300,000 |
Reported balance
Holding disclosure · report date 2010-03-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,300,000 F1: Bristol-Myers Squibb Company ("BMS") recently identified its indirect ownership of 1,300,000 shares of common stock of Kyto Biopharma, Inc. ("Kyto"). These shares are owned directly by Medarex, L.L.C. (formerly known as Medarex, Inc.) ("Medarex"), a wholly-owned subsidiary of BMS. BMS acquired Medarex on September 1, 2009. At that time, Medarex owned 1,300,000 Kyto shares but only provided BMS with a stock certificate, in the name of Kyto's predecessor company B. Twelve, Inc., for 400,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Bristol-Myers Squibb Company ("BMS") recently identified its indirect ownership of 1,300,000 shares of common stock of Kyto Biopharma, Inc. ("Kyto"). These shares are owned directly by Medarex, L.L.C. (formerly known as Medarex, Inc.) ("Medarex"), a wholly-owned subsidiary of BMS. BMS acquired Medarex on September 1, 2009. At that time, Medarex owned 1,300,000 Kyto shares but only provided BMS with a stock certificate, in the name of Kyto's predecessor company B. Twelve, Inc., for 400,000 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
No transactions match
Try broader filters. Historical coverage is still being backfilled.
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.